Trial reportRespiratory research2013
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.
Trial report in Respiratory research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 94 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial
Who cites it
94 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The incidence of acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Clinical efficacy and safety of anticoagulants in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Therapeutic advances in respiratory diseasePooled it
- Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.Respiratory research · 2020Trial
- Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.Respiratory research · 2019Trial
- Trial
- The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.Chest · 2015Trial
- Honeycomb wall thickening during acute deterioration of idiopathic pulmonary fibrosis: clinical, imaging and prognostic characteristics.Journal of thoracic disease · 2026Article
- Mortality and diagnostic practice variation in interstitial lung disease admissions: insights from a multicentre UK cohort study.BMJ open respiratory research · 2026Article
- Idiopathic Pulmonary Fibrosis: A Comprehensive Review of Risk Factors, Genetics, Diagnosis, and Therapeutic Approaches.Biomedicines · 2026Review
- Diagnostic utility of high-mobility group box 1 for acute exacerbations of idiopathic pulmonary fibrosis.Scientific reports · 2025Observational
- Development and Validation of a Clinical Scoring System Predicting 30-Day Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Respirology (Carlton, Vic.) · 2025Article
- Measurement and Significance of the Diffusing Capacity of the Lung for Carbon Monoxide.Clinics in chest medicine · 2025Review
- Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease.Scientific reports · 2025Article
- Effect of Novel Inflammatory Biomarkers on Adverse Outcomes in Patients with Interstitial Lung Disease and Pneumonia: A Multicenter Retrospective Cohort Study.Combinatorial chemistry & high throughput screening · 2025Article
- Role of blood Krebs von Lungen-6 in predicting acute exacerbation in patients with idiopathic pulmonary fibrosis.PloS one · 2025Article
- Acute exacerbations in patients with progressive pulmonary fibrosis.ERJ open research · 2024Article
- Clinical Evaluation of Acute Exacerbation of Interstitial Lung Disease in a Single Tertiary Center: Perspectives before and after the Coronavirus Disease 2019 Pandemic.Journal of clinical medicine · 2024Article
- Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study).BMC pulmonary medicine · 2024Observational
- Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments.Journal of thoracic disease · 2024Review
- High-Flow Nasal Cannula System in Respiratory Failure Associated with Interstitial Lung Diseases: A Systematic Review and Narrative Synthesis.Journal of clinical medicine · 2024Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAcute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure.
methodsThree investigators retrospectively reviewed subjects enrolled in the Sildenafil Trial of Exercise Performance in IPF who experienced a respiratory serious adverse event during the course of the study. Events were classified as definite acute exacerbation, suspected acute exacerbation, or other, according to established criteria.
resultsThirty-five events were identified. Four were classified as definite acute exacerbation, fourteen as suspected acute exacerbation, and seventeen as other. Definite and suspected acute exacerbations were clinically indistinguishable. Both were most common in the winter and spring months and were associated with a high risk of disease progression and short-term mortality.
conclusionsIn this study one half of respiratory serious adverse events were attributed to definite or suspected acute exacerbations. Suspected acute exacerbations are clinically indistinguishable from definite acute exacerbations and represent clinically meaningful events. Clinical trialists should consider capturing both definite and suspected acute exacerbations as outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.